The successful clinical implementation of FGFR2 and IDH1 inhibitors underscores the feasibility and therapeutic value of molecularly tailored interventions in the management of cholangiocarcinoma [64,65,66,67,68]. This evidence concerns the gene IDH1 and cholangiocarcinoma.